Abbreviations: (C max ) maximal plasma insulin concentration, (IV) intravenous, (MI) monomeric insulin, (NPH) neutral protamine Hagedorn, (PK) pharmacokinetic, (RI) regular insulin, (SC) subcutaneous, (t max ) time to maximal concentration Abstract Objective:
Introduction
Thi s study reports the validation of an identified physiological compartment model of plasma insulin appearance from subcutaneous (SC) injection that is presented in this journal. A range of clinically current insulin types were modeled, specifically the prandial insulins monomeric insulin (MI) and regular insulin (RI) and the intermediate-and long-acting basal insulins neutral protamine Hagedorn (NPH) and glargine. The older insulin types lente and ultralente were also modeled. This facility enabled retrospective data of patients treated with these insulin types to be used for model identification and validation. The model was identified previously with good precision in all identified parameters using a wide range of clinical data, and this validation study aims to gauge the accuracy of this model identification using published pharmacokinetic summary measures.
If the intended role of the model is in silico simulation, a Monte Carlo analysis will be used to simulate physiological variability in the pharmacokinetic (PK) profile by transforming published variability (in coefficient of variation) in the key PK summary measures from clinical studies into model parameter probability distributions about the mean parameters identified from mean data. This approach differs from the normal approach of identifying the model on a small cohort of individual patient data, as the amount of information considered is considerably higher and the potential for more accurate simulation is greater.
Model Validation
Data used for model identification and now validation were collected via a literature review of relevant insulin PK studies searched in the MEDLINE and Science Citation Index Expanded (SCI-EXPANDED) databases. Only studies using direct measurement methods were considered. 1 These studies differ widely in cohort studied, methods, and protocol. However, the data is sufficient for this study where the goal is to develop a mean PK simulation model for a diabetes decision support system. A parameter fit and validation across a broad range of studies are likelier to result in an averaged PK response suitable for clinical use over a wide population. However, there are potentially three factors that may affect the accuracy of data:
Insulin antibodies [insulin-dependent diabetes mellitus (IDDM) cohort only]
Endogenous insulin production (noninsulin-dependent diabetes mellitus and normal cohorts only) Insufficient cross-reactivity of test insulin with insulin assay (insulin analogue and animal insulin studies only)
Because of an almost universal lack of availability of spread data for each time point in the majority of these studies, a simpler validation criterion is proposed. Referring to Figure 1 , two common PK summary measures, time to maximal plasma insulin concentration (t max ) and maximal plasma insulin concentration (C max ), for each fitted model curve (t max,model and C max,model ) can be compared to reported clinical values for each data set (t max,data and C max,data ). For these measures, a reported spread over the study for these two parameters (SD t max,data and SD C max,data ) is used to validate the equivalent identified model and results. Other well-accepted measures, including t 50 (half-time to and decrease from peak) and area under curve, are not always reported uniformly by all studies and were thus not used here.
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Conclusions:
A previously derived and identified model was clinically validated for six insulin types using C max and t max summary measures from published pharmacokinetic studies. Hence, this article presents a clinically valid model that accounts for multiple nonlinear effects and six different types of SC insulin in a computationally modest form suitable for use in clinical decision support.
While this validation criterion may not be fully rigorous, it is the only method to assess the model fit to data in the absence of other complete data over several studies. Summary measures such as these are also used very commonly for describing insulin PKs and were thus readily available for most studies, allowing validation criteria comparison across studies. Finally, t max and C max describe the basic and fundamental clinical features of insulin action.
The result of this comparison is shown in Tables 1-6, and a summary is shown in Table 7 . Where t max or C max values are not reported in the study, they are calculated from the mean PK curves used for the parameter identification. All reported measures are unit standardized and expressed as mean ± SD if reported differently. Some values are baseline corrected to match data used for parameter identification. If a summary measure is not reported and bounds cannot be estimated from reported data or if only a mean value was reported with no variation or spread, then the model fit cannot be validated on that particular measure for that particular study.
Possible validation outcomes are therefore limited to the following cases for each study:
The model fit is fully validated if both model curve t max and C max (t max,model or C max,model ) are within SD t max and SD C max The model fit is considered partially validated if only C max,model lies outside ± SD C max,data
If t max,model lies outside t max,data ± SD t max,data , the model fit is invalidated regardless of C max,model . This case choice slightly emphasizes the qualitative shape of the model curve rather than the quantitative plasma insulin concentration. Clearly, the model fit is also invalidated if both model curve t max and C max (t max,model or C max,model ) are outside t max,data ± SD t max,data and C max,data ± SD C max,data
If C max,model cannot be validated but t max,model lies within t max,data ± SD t max,data or vice versa, the model fit is partially validated If both t max,model and C max,model cannot be validated, the model fit cannot be validated overall In case of outcomes e and f, a percentage error is still calculated and shown in Table 7 to provide an estimate of reliability.
Monomeric Insulin Submodel Validation Summary
Referring to Tables 1 and 7, all MI model curve t max and C max values are fully validated (outcome a) except for the study by Shimoda and colleagues, 2 which cannot be validated (outcome f). 
Regular Insulin Submodel Validation Summary
With reference to Tables 2 and 7 for RI data, the study by Davis and associates 3 is invalidated (outcome c) with a very short t max of 30.0 ± 7.9 minutes (for RI), resulting in 90 ± 26% error. This study underestimates t max as it is not corrected for endogenous production, leading to overestimation of plasma insulin appearance in the early part of the trial where insulin production has not been fully suppressed. The 6U RI dose is also insufficient to fully suppress insulin production, which is confirmed by the reported C-peptide measurements. 3 Another study 4 is partially validated (outcome b) with 11.8% C max error considering that insulin antibodies were unaccounted for in the IDDM cohort. Finally, as for MI, the RI model fit to the study by Shimoda and colleagues 2 cannot be validated due to a lack of fully reported data (outcome f).
Neutral Protamine Hagedorn Submodel Validation Summary
For NPH data in Tables 3 and 7, poor model curve t max values were also obtained for Davis et al. 3 and Galloway et al. 5 compared to reported values, as shown in Table 3 . While the model fit to the study by Davis et al. 3 is invalidated (outcome c), the study by Galloway and colleagues 5 is still fully validated because of the use of inadequate normal descriptive statistics for nonnormal data distribution. Similar to the RI study by Davis et al., 3 these two study protocols are both uncorrected for endogenous insulin production and prescribe a relatively low dose (14 units and 0.25 U/kg, respectively) compared to other studies uncorrected for insulin production (0.4 U/kg 6,7 ). Studies by Bottermann et al. 6 and Heinemann et al. 7 used higher comparative insulin doses, and Bottermann and colleagues 6 reported a negligible serum C-peptide concentration for most of the study duration.
Lente and Ultralente Submodel Validation Summary
All lente model fits are fully validated (see Tables 4 and 7) as are all but two ultralente model fits (see Tables 5 and 7) , where studies by Lepore et al. 8 and Owens et al. 9 are partially validated (outcome e) with 20.5 and 8.2% C max error, respectively. 
Insulin Glargine Submodel Validation Summary
For insulin glargine (see Tables 6 and 7) , Heinemann and associates 7 reported measures calculated using a different method to plotted data and cannot be validated. Using the isoglycemic clamp method, another study 8 corrected the plasma insulin concentration for insulin glargine (measured via nonspecific insulin assay) only from 3 hours onward, after the intravenous (IV) insulin infusion rate had decreased to near nil. The origin of the insulin in plasma is thus indeterminate with IV insulin infusion in this time period. Unlike the reported C max (measured between 3 and 24 hours), all insulin measurements were used in the model parameter fit to data, which may have contributed to the C max error of 8.5 ± 6.9% (outcome e).
In summary, it can be seen that 22 model fits are fully validated using both reported t max and C max summary measures, or estimated values from plotted data where not reported (see Table 7) . A further 6 model fits are partially validated on t max only (outcome b) or on C max only if t max cannot be validated (outcome e). All partially validated model fits have errors not exceeding 12% of reported or estimated t max or C max ranges. Validation cannot be performed for 7 model fits due to only a mean reported, or completely unreported, t max and C max , and/or if a range of t max and C max cannot be estimated from plotted data (outcome f). Even then, this error is <30%. Only 2 model fits failed validation with 90 ± 26 and 71 ± 23% error on t max only; in both cases, significant protocol-based reasons were identified and these errors are still <100%. These data was from the same study 3 (for RI and NPH). No model fit was invalidated on both t max and C max measures.
As an additional validation, sample model fits to MI 10 and insulin glargine 8 data are shown in Figures 2 and 3 . The model-generated curve using median or mean parameter values as an overall population value is shown in addition to the individual model fit curve. In both cases the results are excellent matches for data reported in these cases. 
Model Simulation and Outputs
A comparison of model outputs using the population model parameters for an injection of 10 units for all insulin types is shown in Figure 4 . Results are compared to output from the AIDA insulin PK model 11 by Berger and Rodbard, 12 which uses a nonlinear noncompartmental model. This model is one of the foremost SC insulin PK models developed for computer simulation of multiple insulin types and was subsequently applied in the AIDA diabetes education and decision support system. While the most complete of insulin models, it does not model MI or insulin glargine absorption, as it was first published in 1989 before these types were developed. Lepore et al. 8 Note that the plasma insulin concentration is corrected for cross-reactivity with insulin glargine only between 3 and 24 hours, i.e., the first three data points are inaccurate in respect to the exogenous insulin glargine concentration in plasma due to the presence of a not insignificant IV insulin infusion.
As shown in Figure 4 , the dynamics of each modeled insulin type are visually similar between the two models, providing an additional measure of validation.
The model dynamics are also demonstrated for RI concentration dependency and insulin glargine dose dependency in Figure 5 . For a given RI dose, the 
